home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace


phone +1.513.579.9911
email (UK) / (US)
email Medpace 5375 Medpace Way Cincinnati, Ohio 45227

The Promise and Challenge of Adaptive Design in Oncology Trials

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.

Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.

The Promise and Challenge of Adaptive Design in Oncology Trials

Member login

E-mail address:

Remember me

News and Press Releases

New possibilities for researchers - enhanced cell-based assays with microplate readers

Ortenberg, 15.03.2018 (PresseBox) - Cell-based assays have become an important application in the life science sector, from basic to top-level research. They are widely used in biotech companies and academic research institutions to monitor cell health in real-time. As experiments with living cells require constant physiological conditions, a precise gas control is essential. Our latest Atmospheric Control Unit (ACU) is now also available for the Omega series, BMG LABTECH’s budget-friendly product line.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement